CAVA Group, Inc.

Premium valuation is supported by industry-leading same-store sales growth of 9.7% in Q1, a 38% adjusted EBITDA beat, raised full-year guidance, and differentiated menu offerings. Multiple firms including UBS, Stifel, and Baird argue that sustained unit productivity and brand momentum justify the elevated price multiple.

DA Davidson and Morgan Stanley warn that CAVA's stock price already embeds exceptionally high expectations, with a future P/E near 100x leaving virtually no margin for execution missteps. InvestingPro flagged the stock as significantly overvalued at $140, and shares subsequently fell 45%, underscoring downside risk.

CAVA's plan to reach at least 1,000 restaurants by 2032 is backed by healthy new unit returns, growing brand awareness among younger consumers, and analyst consensus projecting 21.4% annual revenue growth. Analysts see significant whitespace in new and underserved markets to support long-term systemwide sales gains.

Aggressive expansion into new markets raises material concerns about market saturation, rising cost pressures, and margin erosion. Increased competition from other health-focused fast-casual brands, combined with a heavy reliance on the Mediterranean concept, could limit CAVA's ability to sustain unit economics at scale.

Q1 comparable sales of 9.7% and Q2-to-date tracking in line with that figure have prompted UBS and several other firms to raise price targets, citing CAVA as a rare growth story in the restaurant sector. Management lifted its full-year same-restaurant sales outlook to 4.5%–6.5%, signaling continued momentum.

A prior slowdown in same-store sales growth, paired with a 2% decline in restaurant traffic that contributed to a 45% stock drawdown from early 2025 highs, demonstrates how fragile comp momentum can be. Elevated short interest and neutral-to-cautious stances from Freedom Capital and Morgan Stanley reflect concern that deceleration could have an outsized valuation impact.